Clinical Impact and Cost-Effectiveness of Updated 2023/24 COVID-19 mRNA Vaccination in High-Risk Populations in the United States DOI Creative Commons
Keya Joshi, Mariia Dronova,

Ewelina Paterak

и другие.

Infectious Diseases and Therapy, Год журнала: 2025, Номер unknown

Опубликована: Апрель 15, 2025

In the post-pandemic era, people with underlying medical conditions continue to be at increased risk for severe COVID-19 disease, yet vaccination uptake remains low. This study estimated clinical and economic impact of updated 2023/24 Moderna among high-risk adults versus no Pfizer/BioNTech vaccination. A static Markov model was adapted adults, including immunocompromised (IC), chronic lung disease (CLD), kidney (CKD), cardiovascular (CVD), diabetes mellitus (DM) populations in United States (US). Vaccination vaccine current coverage rates prevent considerable hospitalizations CLD (101,309), DM (97,358), CVD (47,830), IC (14,834), CKD (13,558) also provided net cost-savings US$399 million (M)-2129M (healthcare payer) $457M-2531M (societal perspective), depending on population. The return-on-investment positive across all ($1.10-$2.60 gain every $1 invested). Healthcare savings a relative 10% increase ($439M-$2342M), from meeting US 2030 targets 70% ($1096M-$5707M). Based higher effectiveness observed real-world evidence studies, additional (13,105), (10,359), (6241), (1979), (942) Pfizer/BioNTech's vaccine, healthcare payer societal cost-savings, making it dominant strategy. per patient vaccinated were $31.00-$59.00, Results robust sensitivity/scenario analyses. Updated provide significant health benefits through prevention populations, payers society, Increasing low cost-saving while preventing many more infections these populations. graphical abstract is available this article.

Язык: Английский

Clinical Impact and Cost-Effectiveness of Updated 2023/24 COVID-19 mRNA Vaccination in High-Risk Populations in the United States DOI Creative Commons
Keya Joshi, Mariia Dronova,

Ewelina Paterak

и другие.

Infectious Diseases and Therapy, Год журнала: 2025, Номер unknown

Опубликована: Апрель 15, 2025

In the post-pandemic era, people with underlying medical conditions continue to be at increased risk for severe COVID-19 disease, yet vaccination uptake remains low. This study estimated clinical and economic impact of updated 2023/24 Moderna among high-risk adults versus no Pfizer/BioNTech vaccination. A static Markov model was adapted adults, including immunocompromised (IC), chronic lung disease (CLD), kidney (CKD), cardiovascular (CVD), diabetes mellitus (DM) populations in United States (US). Vaccination vaccine current coverage rates prevent considerable hospitalizations CLD (101,309), DM (97,358), CVD (47,830), IC (14,834), CKD (13,558) also provided net cost-savings US$399 million (M)-2129M (healthcare payer) $457M-2531M (societal perspective), depending on population. The return-on-investment positive across all ($1.10-$2.60 gain every $1 invested). Healthcare savings a relative 10% increase ($439M-$2342M), from meeting US 2030 targets 70% ($1096M-$5707M). Based higher effectiveness observed real-world evidence studies, additional (13,105), (10,359), (6241), (1979), (942) Pfizer/BioNTech's vaccine, healthcare payer societal cost-savings, making it dominant strategy. per patient vaccinated were $31.00-$59.00, Results robust sensitivity/scenario analyses. Updated provide significant health benefits through prevention populations, payers society, Increasing low cost-saving while preventing many more infections these populations. graphical abstract is available this article.

Язык: Английский

Процитировано

0